(SWX: ARPN) announced that a total of 13 abstracts on iclaprim have
been accepted for the upcoming 18th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID) which takes place in
Barcelona, 19-22 April 2008. ECCMID is a premier European conference where
thousands of scientists and physicians gather to discuss the latest
developments in their field.
Arpida will be presenting additional efficacy and safety data regarding
ASSIST-2, the second pivotal Phase III trial with intravenous iclaprim in
complicated Skin and Skin Structure Infections (cSSSI). Moreover, data from
Phase I studies with intravenous iclaprim, as well as preclinical data will
be presented. Arpida’s senior scientists and external partners have been
invited to present four of the accepted abstracts as oral presentations for
a broad audience at the conference.
The abstracts are expected to be available online on the conference
website starting, 9 April 2008.
About Arpida Ltd.
Arpida (SWX: ARPN) is a biopharmaceutical company with research
facilities in Reinach, Switzerland and in the USA. It focuses on the
discovery and development of novel drugs that seek to overcome the growing
problem of microbial resistance. The most advanced compounds include an
antibacterial under regulatory review and an antifungal in Phase III.
Arpida’s leading product candidate is intravenous iclaprim, a potent
antibacterial that targets severe infections requiring hospital treatment,
including those caused by methicillin-resistant Staphylococcus aureus
(MRSA). The clinical programme for the first indication, complicated skin
and skin structure infections (cSSSI), has been completed. The submission
of the NDA to the US FDA was completed in March 2008.
In December 2007, Arpida announced the enrolment of the first patients
in a Phase II clinical study with intravenous iclaprim in the treatment of
patients with hospital-acquired pneumonia (HAP), ventilator-associated
pneumonia (VAP) or healthcare associated pneumonia (HCAP).
In January 2008, the US FDA granted authorisation to progress oral
iclaprim into a Phase II ‘intravenous-to-oral’ switch trial. Iclaprim could
be offered not only as an intravenous therapy for hospital use in acute
situations, but also as an oral formulation, allowing early patient
discharge followed by outpatient treatment. This switch could be a valuable
instrument in reducing healthcare costs and enhancing patient comfort.
Arpida’s fourth most advanced antibiotic programme, AR-709, targets
upper and lower respiratory tract infections acquired in the community
setting. AR-709 exhibited potent activity against a large panel of
pneumococcal clinical isolates including those resistant to currently used
drugs. Promising results of “first-in-man” studies with AR-709 were
published in March 2007.
An additional compound, AR-2474, has achieved in vivo proof of concept.
AR-2474 has been shown to be effective in eradicating pathogens in
preclinical models of skin infection and nasal carriage.
Apart from the antibiotic programmes, Arpida has an innovative
antifungal therapy (TLT) which is in Phase III clinical trials in Europe,
Moreover, the company has several other leads in optimisation and
additional discovery programmes derived from its own discovery platform at
various research stages.
This press release contains specific forward-looking statements, e.g.
statements including terms like believe, assume, expect or similar
expressions. Such forward-looking statements are subject to known and
unknown risks, uncertainties and other factors which may result in a
substantial divergence between the actual results, financial situation,
development or performance of the company and those explicitly or
implicitly presumed in these statements. Against the background of these
uncertainties readers should not place undue reliance on forward-looking
statements. The company assumes no responsibility to update forward-looking
statements or to adapt them to future events or developments.